Pfizer Inc 1PFE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Pfizer Gets FDA Approval for Expanded Use of Breast-Cancer Treatment Tukysa
-
Vaxcyte Reports Bacterial-Infection Vaccine Met Primary Endpoints in Phase 3 Trial
-
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax — Update
-
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech
-
Pfizer on Pace for Largest Percent Increase Since November 2025 — Data Talk
-
Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance
-
Pfizer Currently Up Eight Days Straight, On Pace for Longest Winning Streak Since April 2021 — Data Talk
-
Pfizer Logs Mixed 2Q on Oncology Growth, Covid-19 Declines
Trading Information
- Previous Close Price
- €24.99
- Day Range
- €25.20–25.48
- 52-Week Range
- €20.45–25.50
- Bid/Ask
- €25.50 / €25.52
- Shares Outstanding
- 5.70B
- Market Cap
- $144.89B
- Volume/Avg
- 16,976 / 6,249
Key Statistics
- Price/Earnings (Normalized)
- 9.72
- Price/Sales
- 2.67
- Dividend Yield (Trailing)
- 5.83%
- Dividend Yield (Forward)
- 6.04%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 5.83%
Company Profile
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 75,000
- Website
- https://www.pfizer.com
Competitors
Valuation
|
Metric
|
1PFE
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 9.72 | 45.31 | 11.56 |
Price/Book Value | 1.94 | 8.56 | 4.02 |
Price/Sales | 2.67 | 5.42 | 2.15 |
Price/Cash Flow | 11.03 | 16.29 | 9.20 |
Price/Earnings
1PFE
MRK
GSK
Financial Strength
|
Metric
|
1PFE
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.85 | 0.71 | 0.52 |
Current Ratio | 1.27 | 1.32 | 0.82 |
Interest Coverage | 2.36 | 4.28 | 9.51 |
Quick Ratio
1PFE
MRK
GSK
Profitability
|
Metric
|
1PFE
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | 8.46% | 6.27% | 11.66% |
Return on Equity (Normalized) | 19.70% | 16.68% | 42.98% |
Return on Invested Capital (Normalized) | 12.66% | 9.82% | 22.63% |
Return on Assets
1PFE
MRK
GSK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|pRG@?dbW | LOCK|t% | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|?<G&vt | LOCK|M$Y | $636B | |||
| AbbVie Inc
ABBV
| LOCK|$XK<yn | LOCK|xC? | $497B | |||
| Merck & Co Inc
MRK
| LOCK|!l?!#Gv | LOCK|kQ | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|$pF?kHv& | LOCK|G!$ | $347B | |||
| Novartis AG ADR
NVS
| LOCK|M$>DZnd | LOCK|fD | $275B | |||
| AstraZeneca PLC
AZN
| LOCK|#q#^%>gj | LOCK|SZ | $247B | |||
| Amgen Inc
AMGN
| LOCK|>#&W<!@# | LOCK|HY@ | $226B | |||
| Gilead Sciences Inc
GILD
| LOCK|v^%hC%h | LOCK|hJ@ | $187B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|pl<Wr?L | LOCK|M< | $170B |
United States